✦ LIBER ✦

833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial

✍ Scribed by Pierre Theroux; Paul W Armstrong; Kenneth W Mahaffey; Judith S Hochman; Scott Rollins; Kevin J Malloy; Thomas Parish; Jose C Nicolau; Joel Lavoie; Christopher B Granger

Book ID: 119548832
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 82 KB
Volume: 43
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(04)91216-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pexelizumab fails to inhibit assembly of

Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial

✍ Catherine Martel; Christopher B. Granger; Marta Ghitescu; Amanda Stebbins; Annik 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 594 KB

Pexelizumab fails to inhibit assembly of

✍ Gen-Min Lin; Yi-Hwei Li; Lamin E.S. Jaiteh; Chih-Lu Han 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB